In the article titled “Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial,”1 published online September 5, 2019, the wrong initial was used for Dr Harding’s middle name. Dr Harding’s correct name is James J. Harding, MD. This article has been corrected online.
Reference
- 1.Abou-Afa GK, Shi Q, Knox J. Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: phase 3 CALGB 80802 randomized clinical trial [published online September 5, 2019]. JAMA Oncol. doi: 10.1001/jamaoncol.2019.2792 [DOI] [PMC free article] [PubMed] [Google Scholar]